ImageWare Detroit Tigers is supplying the COTS Commercial Off
ImageWare describes baseball tickets is supplying kaline autographed bat states the COTS (Commercial Off The Shelf) middleware which allows CATSA to manage the complete identification card life-cycle: enrollment, issuance, verification, card production, auditing, and integration with access control devices. This includes the implementation of the following ImageWare Systems COTS products along with customizations specific to meet the particular needs of CATSA: IWS Biometric Engine(r), IWS EPI Builder, and IWS EPI CMS. The smart chip within the card also stores a unique identifier that is used to confirm user credentials and privileges. The RAIC System will use smart cards containing fingerprint and iris biometrics for tracking secure access for all airport workers (approximately 125,000 individuals). Both biometric algorithms and hardwaredevices can be interchanged at the customers' discretion.A review of previous ImageWare border projects follows: * Canadian Air Transportation Safety Administration (CATSA) For the Canadian Air Transportation Safety Administration (CATSA) ImageWare is currently under contract to supply a new Restricted Access Identity Card (RAIC) software application that enhances aviation security by ensuring that airport worker identities are verified via biometrics and security clearance status is validated before entry is permitted into restricted areas at twenty-nine major airports throughout Canada.
The open architected platform enables users tocreate an application that is capable of utilizing virtually any biometric and amyriad of biometric capture devices detroit tigers . The project will incorporate ImageWare's patented technology forbiometric/identity enrollment, identity vetting, credential issuance, credentialmanagement and access control miguel cabrera . The card will be compliant with the biometric standards set by ICAO,the international organization that sets the standards for passports and traveldocuments tiger sweatshirt . Once anapplicant's finger, face and iris are enrolled along with applicable textinformation, a smart card will be issued to the applicant, which will be usedthereafter to verify the authenticity of the applicant's identity andprivileges yawkey way store . The customer estimates this nextphase will have a revenue value to ImageWare of another $12 million over aneighteen month implementation period."ImageWare's border management software will enable its government customer tobiometrically enroll applicants seeking permission to cross its border. Based on discussions with thegovernment customer, they plan to expand the project in a next phase to includeseaports and airports throughout the country. The combination of ourpatented IWS Biometric Engine(r), IWS EPI Builder and related work flow processtools built specifically for border control will play a major role in thissignificant infrastructure project that will knit biometric identity into thefabric of our client's border control system.
We believe we were selected as a key contributor based on ourextensive track record of providing biometric based identity managementsolutions for border applications and access control with Canadian AirTransportation Safety Administration (CATSA), Citizenship and Immigration Canada(CIC) and Florida Uniform Port Access Credential (FUPAC) detroittigers . The company has receivedthe first task order and has begun work on the project.Jim Miller, ImageWare's chairman and CEO, said, "This government's majorinfrastructure project and our negotiations have been in the works for a verylong time kaline autographed bat . The project consists of four task orders and is expected togenerate in excess of $12 million in revenue over the initial eighteen monthcompletion period if all the task orders are issued miguel cabrera . Pfizer IncMedia:Joan Campion, 212-733-2798orInvestor:Suzanne Harnett, 212-733-8009 Copyright Business Wire 2009 tiger sweatshirt . SAN DIEGO, June 18, 2009 (GLOBE NEWSWIRE) -- ImageWare Systems, Inc. (PinkSheets:IWSY) was selected by an undisclosed government customer to deploy itsBiometric Border Management software product suite at points of entry along thecountry's border. The information contained in Pfizer`s or Wyeth`s websites is notincorporated by reference and does not constitute a part of this press release.
You canfind information about Pfizer`s executive officers and directors in itsdefinitive proxy statement filed with the SEC on March 13, 2009 detroittigers net . You can findinformation about Wyeth`s executive officers and directors in its Annual Reporton Form 10-K for the fiscal year ended December 31, 2008, as amended by Wyeth`sAnnual Report on Form 10-K/A, filed with the SEC on February 27, 2009 and April30, 2009, respectively, and the definitive proxy statement/prospectus forWyeth`s 2009 Annual Meeting of Shareholders, which was filed with the SEC onJune 17, 2009 yawkey way store . Wyeth will mail the proxy statement/prospectus to its stockholders.Pfizer urges investors and security holders to read the proxystatement/prospectus regarding the pending acquisition because it containsimportant information kaline autographed bat . Additional InformationIn connection with the pending acquisition of Wyeth, Pfizer has filed with theSEC, and the SEC has declared effective, a Registration Statement on Form S-4that includes a proxy statement of Wyeth that also constitutes a prospectus ofPfizer . andinternationally and the exposure to litigation and/or regulatory actions.Additional factors that could cause results to differ materially from thosedescribed in the forward-looking statements can be found in Pfizer's 2008 AnnualReport on Form 10-K filed with the Securities and Exchange Commission (the"SEC") on February 27, 2009, Wyeth's 2008 Annual Report on Form 10-K, asamended, filed with the SEC on February 27, 2009, including in the "RiskFactors" section of each of these filings, and each company's other filings withthe SEC available at the SEC's Internet site ( http://). Such statements are based upon the current beliefs andexpectations of Pfizer's and Wyeth's management and are subject to significantrisks and uncertainties. Actual results may differ from those set forth in theforward-looking statements.